Redeye: Alligator Bioscience - Can Alligator bite back?
Redeye reevaluates Alligator Bioscience ahead of its first efficacy readout from mitazalimab later this year. Success with this can reverse the share’s turbulent ride since the return of mitazalimab from Janssen in 2019. In addition, Alligator’s other projects are advancing and nearing inflexion points, offering diversification options.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/